ANGPTL3 Deficiency and Protection Against Coronary Artery Disease

Familial combined hypolipidemia, a Mendelian condition characterized by substantial reductions in all 3 major lipid fractions, is caused by mutations that inactivate the gene angiopoietin-like 3 (ANGPTL3). Whether ANGPTL3 deficiency reduces risk of coronary artery disease (CAD) is unknown. The study...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal of the American College of Cardiology Ročník 69; číslo 16; s. 2054
Hlavní autoři: Stitziel, Nathan O, Khera, Amit V, Wang, Xiao, Bierhals, Andrew J, Vourakis, A Christina, Sperry, Alexandra E, Natarajan, Pradeep, Klarin, Derek, Emdin, Connor A, Zekavat, Seyedeh M, Nomura, Akihiro, Erdmann, Jeanette, Schunkert, Heribert, Samani, Nilesh J, Kraus, William E, Shah, Svati H, Yu, Bing, Boerwinkle, Eric, Rader, Daniel J, Gupta, Namrata, Frossard, Philippe M, Rasheed, Asif, Danesh, John, Lander, Eric S, Gabriel, Stacey, Saleheen, Danish, Musunuru, Kiran, Kathiresan, Sekar
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 25.04.2017
Témata:
Adult
Angiopoietin-Like Protein 3
Angiopoietin-like Proteins
Angiopoietins - blood
Angiopoietins - deficiency
Angiopoietins - genetics
Animals
Atherosclerosis - genetics
Case-Control Studies
Coronary Artery Disease - genetics
Female
Humans
Lipids - blood
Male
Mice, Inbred C57BL
Mice, Knockout
Middle Aged
Mutation, Missense
Myocardial Infarction - blood
Risk Factors
human genetics
loss-of-function mutations
myocardial infarction
ISSN:1558-3597, 1558-3597
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Familial combined hypolipidemia, a Mendelian condition characterized by substantial reductions in all 3 major lipid fractions, is caused by mutations that inactivate the gene angiopoietin-like 3 (ANGPTL3). Whether ANGPTL3 deficiency reduces risk of coronary artery disease (CAD) is unknown. The study goal was to leverage 3 distinct lines of evidence-a family that included individuals with complete (compound heterozygote) ANGPTL3 deficiency, a population based-study of humans with partial (heterozygote) ANGPTL3 deficiency, and biomarker levels in patients with myocardial infarction (MI)-to test whether ANGPTL3 deficiency is associated with lower risk for CAD. We assessed coronary atherosclerotic burden in 3 individuals with complete ANGPTL3 deficiency and 3 wild-type first-degree relatives using computed tomography angiography. In the population, ANGPTL3 loss-of-function (LOF) mutations were ascertained in up to 21,980 people with CAD and 158,200 control subjects. LOF mutations were defined as nonsense, frameshift, and splice-site variants, along with missense variants resulting in <25% of wild-type ANGPTL3 activity in a mouse model. In a biomarker study, circulating ANGPTL3 concentration was measured in 1,493 people who presented with MI and 3,232 control subjects. The 3 individuals with complete ANGPTL3 deficiency showed no evidence of coronary atherosclerotic plaque. ANGPTL3 gene sequencing demonstrated that approximately 1 in 309 people was a heterozygous carrier for an LOF mutation. Compared with those without mutation, heterozygous carriers of ANGPTL3 LOF mutations demonstrated a 17% reduction in circulating triglycerides and a 12% reduction in low-density lipoprotein cholesterol. Carrier status was associated with a 34% reduction in odds of CAD (odds ratio: 0.66; 95% confidence interval: 0.44 to 0.98; p = 0.04). Individuals in the lowest tertile of circulating ANGPTL3 concentrations, compared with the highest, had reduced odds of MI (adjusted odds ratio: 0.65; 95% confidence interval: 0.55 to 0.77; p < 0.001). ANGPTL3 deficiency is associated with protection from CAD.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1558-3597
1558-3597
DOI:10.1016/j.jacc.2017.02.030